Abstract
The majority of episodes of syncope are innocent and will not occur again. However, in certain instances, in particular when associated with brady- or tachyarrhythmias, syncope is more likely to be recurrent or predict risk of sudden death. A comprehensive evaluation including patient history, physical examination, and directed investigations allows the clinician to discriminate between innocent and sinister syncope. Arrhythmic syncope is typically associated with minimal prodrome or postdrome, and a higher risk of injury. Identification of the key presenting features is the first step in risk stratification and directs the clinician to an optimal investigation strategy and, as such, timely diagnosis and treatment.
This chapter describes the features that characterize arrhythmic syncope, and the recognition and management of the culprit arrhythmia. This will include a focus on the initial evaluation of the syncopal patient that distinguishes primary tachy- and bradyarrhythmias from the other forms of syncope and pseudosyncope. An approach to interpretation of symptomatic and asymptomatic arrhythmias is outlined. Appropriate diagnostic testing including the approach to various forms of cardiac monitoring leads to a diagnosis, which is typically associated with definitive therapy, ranging from medical and device therapy to catheter ablation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Linzer M, Yang EH, et al. Diagnosing syncope. Part 2: Unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med. 1997;1:76–86.
Alboni P, Brignole M, et al. Diagnostic value of history in patients with syncope with or without heart disease. J Am Coll Cardiol. 2001;7:1921–8.
Sarasin FP, Louis-Simonet M, et al. Prospective evaluation of patients with syncope: a population-based study. Am J Med. 2001;3:177–84.
Khairy P, Van Hare GF, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Can J Cardiol. 2014;10:e1–e63.
Brito-Zeron P, Izmirly PM, et al. The clinical spectrum of autoimmune congenital heart block nature reviews. Rheumatology. 2015;5:301–12.
Baruteau AE, Perry JC, et al. Evaluation and management of bradycardia in neonates and children. Eur J Pediatr. 2016;2:151–61.
Bordachar P, Zachary W, et al. Pathophysiology, clinical course, and management of congenital complete atrioventricular block. Heart Rhythm. 2013;5:760–6.
Rezazadeh S, Duff HJ. Genetic determinants of hereditary bradyarrhythmias: a contemporary review of a diverse group of disorders. Can J Cardiol. 2017;6:758–67.
Krahn AD, Healey JS, et al. Systematic assessment of patients with unexplained cardiac arrest: cardiac arrest survivors with preserved ejection fraction registry (CASPER). Circulation. 2009;4:278–85.
Priori SG, Wilde AA, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;12:1932–63.
Rohatgi RK, Sugrue A, et al. Contemporary outcomes in patients with long QT syndrome. J Am Coll Cardiol. 2017;4:453–62.
Mazzanti A, Maragna R, et al. Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with long QT syndrome. J Am Coll Cardiol. 2018;15:1663–71.
Hosseini SM, Kim R, et al. Reappraisal of reported genes for sudden arrhythmic death. Circulation. 2018;12:1195–205.
Antzelevitch C, Yan GX, et al. J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. Heart Rhythm. 2016;10:e295–324.
Priori SG, Napolitano C, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;2:196–200.
Roston TM, Vinocur JM, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry Circulation. Arrhythmia Electrophysiol. 2015;3:633–42.
Van der Werf C, Lieve KV, et al. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart J. 2019;35:2953–61.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bennett, M.T., Roston, T.M., Sanatani, S., Krahn, A.D. (2020). Bradycardias and Tachycardias: Acquired and Inheritable. In: Brignole, M., Benditt, D. (eds) Syncope. Springer, Cham. https://doi.org/10.1007/978-3-030-44507-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-44507-2_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-44506-5
Online ISBN: 978-3-030-44507-2
eBook Packages: MedicineMedicine (R0)